Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

a shareholders to vote on this transaction is scheduled to occur in January 2010.

    Nimotuzumab

    Nimotuzumab is currently being evaluated in 32 Phase II and III clinical
trials, 11 of which are being conducted by YM's majority owned subsidiary,
CIMYM BioSciences Inc., or its licensees.

    -   Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab in Japan,
        and YM's licensee in Korea, Kuhnil Pharmaceutical Co., are currently
        collaborating on a randomized, open-label Phase II trial evaluating
        nimotuzumab plus irinotecan compared to irinotecan alone in patients
        with advanced or recurrent gastric cancer refractory to 5-FU-
        containing regimens which is reportedly expected to complete
        recruitment in calendar 2009. Daiichi Sankyo is also conducting a
        Phase II trial in first-line NSCLC for which completion of
        recruitment is reportedly expected in the first half of 2010.

    -   YM initiated randomized, double-blind Phase II, trials in patients
        with brain metastases from non-small cell lung cancer (NSCLC) and in
        NSCLC patients ineligible for radical chemotherapy. Recruitment
        commenced in Canada in March 2009 for palliative NSCLC and in
        September for the brain metastases trial. A Phase II, second-line,
        single-arm trial in children with progressive diffuse intrinsic
        pontine glioma (DIPG) is ongoing at multiple sites in the US, Canada,
        and Israel.

    -   Oncoscience AG (OSAG), CIMYM's licensee for Europe, reported
        completion of recruitment in a single-arm, Phase III trial of
        nimotuzumab as first-line therapy for DIPG in August 2007, and the
        preliminary data from this trial that was released at ASCO in 2008
        was expanded on at the annual international pediatric oncology forum,
        SIOP, held in Sao Paulo, Brazil in October 2009. OSAG advises that,
        based on the data it plans to submit a Pediatr
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical ... relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks ... and regulatory pathways., , Stem Cell Meeting on the ...
(Date:8/25/2015)... 25, 2015   WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical ... with 20 years of operations in China ... signed an agreement whereby WuXi,s Laboratory Testing Division (LTD) ...
(Date:8/25/2015)... Menomonie, Wis. (PRWEB) , ... August 25, 2015 ... ... and fermentor at its research facility in Knapp, Wis. The company has added ... Biostat C15 Fermentor allows detailed data collection during bacterial or fungal fermentation process ...
(Date:8/25/2015)... ... 2015 , ... One of the world’s foremost authorities on supply chain risk ... been on a mission for the past two weeks. She’s been scrambling to warn ... the two massive explosions that occurred on August 12 at the Ruihai International Logistics ...
Breaking Biology Technology:PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3New centrifuge and fermentor expand product development capacity at Vets Plus 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... the Board of Directors,meeting held today, the Directors ... The dividend is payable on December 15, 2008 ... About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science ... products and kits,are used in scientific and genomic ...
... 11 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ... due to the technical difficulties encountered on,today,s conference ... tomorrow,Wednesday, November 12, 2008. On this call, BMP ... since technical difficulties prevented the,Company from addressing all ...
... molecule detection to expand prominent Scientific Advisory ... ... 11 Quanterix Corporation, the,leader in single molecule detection, announced today ... Corn is a,Professor in the Departments of Chemistry and Biomedical Engineering ...
Cached Biology Technology:BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 2BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 3Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board 2
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... Boston University School of Medicine (BUSM) have identified a ... response and homeostasis. These findings could help lead to ... associated with cancer, type 2 diabetes and other diseases. ... PhD, assistant professor of biochemistry at BUSM, was done ...
... This press release is available in German . ... is a key feature of human evolution. In particular, humans ... individuals. Chimpanzees and orangutans, two of our closest living relatives, ... generation to another. Whether and how this process resembles the ...
... a warning for obese women who are planning pregnancies. Even if ... will develop in an unhealthy environment that places the infants at ... in the placentas of obese mothers when it should be going ... in the placenta of an obese mother is half the size ...
Cached Biology News:BUSM researchers identify key regulator of inflammatory response 2Majority-biased learning 2U of I study: Lose body weight before gaining baby weight 2
Request Info...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
Request Info...
Biology Products: